The Frontotemporal Dementia (FTD) therapeutic landscape encompasses the complete spectrum of treatment approaches, from currently available symptomatic therapies to disease-modifying treatments in development. FTD represents a challenging therapeutic area due to its clinical heterogeneity and underlying pathology (tau, TDP-43, or FUS). This page provides a comprehensive map of the therapeutic ecosystem.
Last updated: 2026-03-20
¶ Current Treatment Landscape
No disease-modifying therapies are currently FDA-approved for FTD. This remains a critical unmet need. The only FDA-approved neurodegenerative disease-modifying treatments are amyloid-targeting antibodies for Alzheimer's disease (lecanemab, donanemab).
| Drug Class |
Agents |
Indication |
Evidence Level |
| SSRIs |
Citalopram, sertraline, fluoxetine |
Behavioral symptoms (disinhibition, anxiety, OCD) |
Moderate |
| Atypical antipsychotics |
Risperidone, quetiapine |
Agitation, aggression |
Limited; caution for mortality risk |
| Stimulants |
Methylphenidate, modafinil |
Apathy |
Limited |
| Anticonvulsants |
Valproate, carbamazepine |
Mood stabilization |
Weak |
| NMDA antagonist |
Memantine |
Cognitive symptoms |
Mixed results |
| Benzodiazepines |
Lorazepam, clonazepam |
Anxiety, RBD |
Short-term only |
- Speech and language therapy for PPA variants
- Occupational therapy for functional maintenance
- Behavioral modification strategies
- Caregiver education and support
- Environmental modifications
Tau pathology is present in approximately 40% of FTD cases (primarily MAPT mutations and CBD/PSP overlap).
| Drug |
Company |
Mechanism |
Development Phase |
Notes |
| Semorinemab |
Roche/Genentech |
Monoclonal antibody targeting tau N-terminus |
Phase 2 |
Neutralizing extracellular tau |
| Gosuranemab |
Biogen |
Anti-tau antibody |
Phase 2 |
Completed; did not meet primary endpoint |
| Lecanemab |
Eisai/Biogen |
Anti-amyloid beta protofibrils |
Phase 2 (FTD substudy) |
Approved for AD |
| Tilavonemab |
AbbVie |
Anti-tau antibody |
Phase 1/2 |
|
| Drug |
Company |
Mechanism |
Development Phase |
| LMTM (Leuco-methylthioninium) |
TauRx |
Tau aggregation inhibitor |
Phase 3 (completed) |
| Sodium phenylbutyrate/taurursodiol |
Amylyx |
Unclear |
Phase 2 |
| Target |
Compound |
Company |
Phase |
| GSK-3β |
Tideglusib |
Novartis |
Phase 2 |
TDP-43 pathology is present in approximately 50% of FTD cases (most sporadic FTD, GRN mutations, C9orf72).
| Drug |
Company |
Target |
Development Phase |
| BIIB100 |
Biogen |
TDP-43 |
Phase 1/2 |
| ASO targeting TDP-43 |
Ionis/Alnylam |
TDP-43 mRNA |
Preclinical |
| ION363 (Fischer) |
Ionis |
TDP-43 |
Phase 1/2 |
| Approach |
Target |
Company |
Phase |
| AAV-TARDBP-siRNA |
TDP-43 |
Various |
Preclinical |
| Approach |
Drug |
Company |
Phase |
| Progranulin replacement |
AAV-GRN |
Prevail Therapeutics/Pfizer |
Phase 1/2 |
| Progranulin augmentation |
AT-GAA |
-- |
Preclinical |
| Gene silencing |
ASO-GRN |
Ionis |
Phase 1 |
| Approach |
Drug |
Company |
Phase |
| Gene silencing |
ASO-C9orf72 |
Ionis/Biogen |
Phase 1/2 |
| Gene silencing |
siRNA |
Various |
Preclinical |
| Approach |
Target |
Phase |
| Tau ASO |
MAPT mRNA |
Phase 1/2 |
| Tau gene editing |
MAPT |
Preclinical |
Microglial activation is a key contributor to FTD progression.
| Target |
Approach |
Drug |
Company |
Phase |
| TREM2 |
Agonist |
AL002 |
Alector/AbbVie |
Phase 2 |
| TREM2 |
Agonist |
PY314 |
PYC Therapeutics |
Phase 1 |
| CSF1R |
Inhibitor |
PLX3397 |
Plexxikon |
Phase 1/2 |
| IL-6 |
Antibody |
Tocilizumab |
Roche |
Phase 2 |
| Approach |
Target |
Phase |
| AAV-CNTF |
Ciliary neurotrophic factor |
Phase 1/2 |
| AAV-GDNF |
Glial cell line-derived neurotrophic factor |
Preclinical |
¶ Clinical Trial Landscape
| Phase |
Active Trials |
Completed |
Total |
| Phase 1 |
34 |
50+ |
84+ |
| Phase 2 |
46 |
80+ |
126+ |
| Phase 3 |
12 |
40+ |
52+ |
| Total |
~124 |
~172 |
~380 |
| Trial ID |
Drug |
Mechanism |
Phase |
Sponsor |
| NCT04345601 |
Semorinemab |
Anti-tau |
Phase 2 |
Roche |
| NCT04735561 |
BIIB100 |
TDP-43 ASO |
Phase 1/2 |
Biogen |
| NCT05462106 |
AL002 |
TREM2 agonist |
Phase 2 |
Alector |
| NCT05635007 |
AAV-GRN |
Progranulin |
Phase 1/2 |
Pfizer |
- Adaptive trials allowing mid-study modifications
- Platform trials testing multiple therapies simultaneously
- Basket trials enrolling patients by biomarker rather than diagnosis
- Remote/hybrid trials reducing patient burden
¶ Key Companies and Programs
| Company |
FTD Programs |
Key Assets |
| Biogen |
TDP-43, C9orf72 |
BIIB100, ASO-C9 |
| Roche/Genentech |
Tau |
Semorinemab |
| Eisai |
Tau, amyloid |
Lecanemab, elenbecestat |
| Pfizer/Prevail |
GRN |
AAV-GRN |
| AbbVie |
TREM2, tau |
AL002, tau antibodies |
| Alector |
TREM2 |
AL002, AL003 |
| Ionis |
Genetic ASOs |
Multiple programs |
| TauRx |
Tau aggregation |
LMTM |
| Company |
Focus Area |
Stage |
| Cerevel |
D1/D2 agonists |
Phase 2 |
| AC Immune |
Tau vaccines |
Phase 1/2 |
| Prothelia |
Progranulin |
Preclinical |
| Vigil |
TREM2 |
Preclinical |
¶ Target Landscape Summary
| Target |
Rationale |
Therapeutic Modality |
Development Stage |
| Tau |
40% of FTD cases |
Antibodies, ASOs |
Phase 2 |
| TDP-43 |
50% of FTD cases |
ASOs, gene therapy |
Phase 1/2 |
| GRN |
~10% of FTD (genetic) |
Gene therapy, ASO |
Phase 1/2 |
| C9orf72 |
~10% of FTD (genetic) |
ASOs |
Phase 1/2 |
| Target |
Rationale |
Development Stage |
| TREM2 |
Microglial dysfunction |
Phase 2 |
| CSF1R |
Microglial modulation |
Phase 1/2 |
| IL-6 |
Neuroinflammation |
Phase 2 |
| RNA splicing modifiers |
TDP-43 function |
Preclinical |
| Biomarker |
Target |
Utility |
Development Stage |
| NfL (Neurofilament Light) |
Axonal damage |
Progression marker |
Clinical use |
| p-tau181/217 |
Tau pathology |
Diagnostic |
Clinical validation |
| NGP (Neurogranin) |
Synaptic dysfunction |
Research use |
|
| Progranulin |
GRN mutations |
Diagnostic |
Clinical use |
| Modality |
Target |
Utility |
| Tau PET |
Tau pathology |
Diagnostic, trial enrichment |
| FDG-PET |
Metabolic changes |
Differential diagnosis |
| MR volumetry |
Atrophy progression |
Disease progression |
¶ Regulatory Landscape
- AL002 (TREM2 agonist): Granted BTD for FTD
- AAV-GRN: Granted Rare Pediatric Disease designation
- BIIB100: Granted Fast Track designation
- Heterogeneous patient populations requiring biomarker stratification
- Lack of validated clinical endpoints specific to FTD
- Long trial durations needed to demonstrate disease modification
- Regulatory harmonization across jurisdictions
¶ Challenges and Opportunities
- Diagnostic accuracy - FTD often misdiagnosed as AD or psychiatric disorders
- Patient heterogeneity - Multiple clinical and pathological subtypes
- Biomarker development - Need for surrogate endpoints
- Trial recruitment - Smaller patient populations than AD
- Long natural history - Slow progression complicates endpoint selection
- Genetic FTD subtypes - Well-defined populations for targeted therapies
- Biomarker stratification - Enable precision medicine approaches
- Platform trials - Increase efficiency of development
- Regulatory engagement - Early and continuous dialogue
- Patient registries - Build trial-ready cohorts